FDA Doesn’t Need New “Hammers” For Drug Safety, Gottlieb Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Deputy commissioner says that improving technology, not revamping the agency’s oversight authority, will lead to post-marketing improvements.
You may also be interested in...
Drug Safety Bill From Sens. Kennedy And Enzi Faces Rival Version In The House
Reps. Waxman and Markey introduce legislation to give FDA stronger post-market enforcement authority, including higher fines than in a Senate version of the bill.
Drug Safety Bill From Sens. Kennedy And Enzi Faces Rival Version In The House
Reps. Waxman and Markey introduce legislation to give FDA stronger post-market enforcement authority, including higher fines than in a Senate version of the bill.
Deputy Commissioner Scott Gottlieb To Leave FDA Jan. 16
Gottlieb will return to the American Enterprise Institute to work on health policy issues with former FDA/CMS chief Mark McClellan.